Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic, primary left-sided, unresectable colorectal cancer: The CR-SEQUENCE - CR-SEQUENCE

Grupo de Tratamiento de los Tumores Digestivos (TTD)0 个研究点目标入组 370 人开始时间: 2018年6月27日最近更新: 2018年11月12日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 370

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1)Man or woman at least 18 years old.
•2)Capable of understand, sign and date an informed consent approved by an IEC.
•3)Histologically confirmed adenocarcinoma of the left colon or rectum (originate in the splenic flexure, descending colon, sigmoid colon, or rectum) in patients with unresectable (not amenable to radical surgery of metastases at the study inclusion) metastatic (M1) disease.
•4)Patients who had wild-type RAS status confirmed as per standard of care according to international guidelines prior to first-line initiation.
•*RAS analysis should include at least KRAS exons 2, 3 and 4 (codons 12, 13, 59, 61, 117 and 146) and NRAS exons 2, 3 and 4 (codons 12, 13, 59, 61 and 117).
•5)At least one unidimensionally measurable lesion per RECIST criteria (version 1.1).
•6)ECOG performance status < 2.
•7)Adequate bone marrow function: neutrophils =1.5 x109/ L; platelets =100 x109/L; haemoglobin =9 g/dL.
•8)Hepatic, renal and metabolic function as follows:
•-Total bilirubin count =1.5 x upper limit of normal (ULN), serum glutamic pyruvic transaminase/alanine aminotransferase (SGPT/ALT) and serum glutamic oxaloacetic transaminase/aspartate aminotransferase (SGOT/AST). = 2.5 x ULN (5 x ULN for subjects with liver involvement of their cancer or 10 x ULN for subjects with bone involvement).
•-Renal function, calculated as creatinine clearance or 24-hour creatinine clearance = 50 mL/min.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 185
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 185

排除标准

•1)History of prior or concurrent central nervous system metastases.
•2)History of another primary cancer, except: curatively treated in situ cervical cancer, or curatively resected non-melanoma skin cancer, or other primary solid tumour curatively treated with no known active disease present and no treatment administered for = 5 years before randomization.
•3)Prior chemotherapy or other systemic anticancer therapy for treatment of metastatic colorectal carcinoma.
•4)Prior adjuvant chemotherapy for colorectal cancer (stage I, II or III) terminated less than 6 month before metastatic disease was diagnosed.
•5)Unresolved toxicities of a previous systemic treatment that, in the opinion of the Investigator, cause the patient unfit for inclusion.
•6)Prior use (as monotherapy or adjuvant treatment) of anti-EGFR antibody therapy (e.g. cetuximab), anti-VEGF or small molecule EGFR inhibitors (e.g. erlotinib).
•7)Prior hormonal therapy, immunotherapy or approved or experimental antibody/proteins = 30 days before inclusion.
•8)Significant cardiovascular disease including unstable angina or myocardial infarction within 12 months before initiating study treatment or a history of ventricular arrhythmia.
•9)Uncontrolled hypertension.
•10)History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline chest computerised tomography (CT).
•11)Treatment for systemic infection within 14 days before the start of study treatment.
•12)Acute or subacute intestinal occlusion and/or active inflammatory bowel disease or other bowel disease that causes chronic diarrhoea (defined as grade = 2 diarrhoea according to NCI-CTCAE version 4.03).
•13)Clinically significant peripheral sensory neuropathy.
•14)Evidence of previous acute hypersensitivity reaction, of any grade, to any component of the treatment.
•15)History of Gilbert disease or known dihydropyrimidine deficiency syndrome.
•16)Recent (within 6 months before the start of study treatment) gastroduodenal ulcer to be active or uncontrolled.
•17)Recent (within 6 months before the start of study treatment) pulmonary embolism, deep vein thrombosis, or other significant venous event.
•18)Pre-existing bleeding diathesis and/or coagulopathy with exception of well-controlled anticoagulation therapy (within 6 months before the start of study treatment)
•19)Recent (within 4 weeks prior to inclusion study) major surgical procedure, open biopsy, or significant traumatic injury not yet recovered from prior major surgery
•20)History of any disease that may increase the risks associated with study participation or may interfere with the interpretation of study results.
•21)Known positive test for human immunodeficiency virus infection, hepatitis C virus, and chronic active hepatitis B infection.
•22)Any disorder that compromises the patient’s ability to provide written informed consent and/or comply with study procedures.
•23)Any investigational agent within 30 days prior to inclusion.
•24)Pregnant or breastfeeding woman.
•25)Surgery (excluding diagnostic biopsy or placement of a central venous catheter) and/or radiotherapy within 28 days prior to inclusion in the study.
•26)Male or female of childbearing age who do not agree with taking adequate contraceptive precautions, i.e. use contraception double barrier (e.g. diaphragm plus condoms) or abstinence during the course of the study and for 6 months after the last administration of study drug for women and 1 month for men.

研究者

发起方

Grupo de Tratamiento de los Tumores Digestivos (TTD)

相似试验

进行中（未招募）

1 期

Clinical trial to evaluate the efficacy and safety of sorafenib followed by pazopanib compared to the treatment setting pazopanib followed by sorafenib in the treatment of advanced /metastatic renal cancerAdvanced / metastatic renal cell carcinomaMedDRA version: 19.0Level: PTClassification code 10038410Term: Renal cell carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2011-004396-36-NLFakultät für Medizin der Technischen Universität München377

已完成

3 期

Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinomaadvanced / metastatic renal cell carcinomaadvanced/ disseminated renal cell kidney cancer10038364

NL-OMON43677Dekan der Fakultät für Medizin der Technischen Universität München45

进行中（未招募）

1 期

EUCTR2011-004396-36-ATFakultät für Medizin der Technischen Universität München377

进行中（未招募）

1 期

Clinical trial to evaluate the efficacy and safety of sorafenib followed by pazopanib compared to the treatment setting pazopanib followed by sorafenib in the treatment of advanced /metastatic renal cancerAdvanced / metastatic renal cell carcinomaMedDRA version: 19.1Level: PTClassification code 10038410Term: Renal cell carcinoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.1Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2011-004396-36-DEFakultät für Medizin der Technischen Universität München377

进行中（未招募）

1 期

Clinical trial to compare the efficacy of two treatment sequencing schemes with chemotherapy (the regime called FOLFOX and FOLFIRI) in combination with biologic drugs (panitumumab and bevacizumab).Metastatic colorectal cancerMedDRA version: 21.0Level: LLTClassification code: 10052362Term: Metastatic colorectal cancer Class: 10029104

CTIS2024-510967-41-00Asociacion Grupo Tratamiento De Tumores Digestivos416